Management of Third Stage of Labour;

Afridi, Nighat; Faridi, Manzoor Ahmed

doi:10.29309/tpmj/2008.15.01.2695

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous Cochrane review deduced that syntometrine (oxytocin/ergometrine) is related to a considerable decrease in the PPH risk for loss of blood, which exceed 500 mL but not 1,000 mL when compared to using oxytocin alone. However, the side effects of syntometrine as nausea, vomiting, pain, and hypertension (with a high incidence of 20 - 30% in Western countries ( 10 , 11 )), retained placenta ( 12 ), coronary artery spasm ( 13 ), and intracerebral hemorrhage ( 14 ). These side effects are mainly due to the ergometrine component.…”

Section: Introductionmentioning

confidence: 99%

Hemodynamic Effects of Oxytocin and Carbetocin During Elective Cesarean Section in Preeclamptic Patients Under Spinal Anesthesia: A Randomized Double-blind Controlled Study

Bahr¹,

Alkhatip²,

Ahmed³

et al. 2023

Anesth Pain Med

View full text Add to dashboard Cite

Background: Oxytocin and carbetocin are uterotonic medications that are used to decrease postpartum hemorrhage (PPH). However, there are not enough clinical data about the hemodynamic side effects of carbetocin. Objectives: This study aimed to compare carbetocin and oxytocin hemodynamic effects in preeclamptic patients undergoing elective cesarean section under spinal anesthesia. Methods: In this double-blind, randomized controlled trial, intravenous oxytocin or carbetocin was administered to 80 women (40 per group). The hemodynamic effects, such as blood pressure (BP), heart rate (HR), and oxygen (O2) saturation, were measured before the operation and after 1, 5, 10, and 15 minutes of the administration of both drugs. Intragroup and intergroup comparisons were conducted during statistical analysis. Results: Based on the intragroup comparison, there was a significant increase in HR and a reduction in BP from baseline to all intervals after the administration of both interventions. Moreover, based on the intergroup comparison, there was a significantly more increase in HR and a decline in BP and O2 saturation in the oxytocin group than in the carbetocin group. There were three and seven cases that required another dose of carbetocin and oxytocin, respectively. Moreover, one case developed PPH in the carbetocin group; nevertheless, two cases developed PPH in the oxytocin group. Conclusions: The minimal effect of carbetocin on patients’ hemodynamics suggests extending the use of this drug instead of oxytocin as a uterotonic drug in patients with preeclampsia, hemorrhagic risk factors, and/or hypertension.

show abstract